Overview

A Study of Combination Therapies With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Status:
Not yet recruiting

Trial end date:
2025-11-26

Target enrollment:

Participant gender:

Summary

This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to programmed cell death 1 protein (PD-1)/ programmed cell death ligand 1 (PD-L1) based treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Immunoglobulins
Irinotecan
Lenvatinib
Paclitaxel
Pembrolizumab